Results     27-May-24
Analysis
Divis Laboratories
NP up 67.6%
For the quarter ending March 2024, consolidated Net sales (including other operating income) of Divis Laboratories has increased 18.04% to Rs 2303 crore compared to quarter ended March 2023.  Operating profit margin has jumped from 24.96% to 31.74%, leading to 50.10% rise in operating profit to Rs 731.00 crore.  Raw material cost as a % of total sales (net of stock adjustments) decreased from 41.82% to 38.96%.   Employee cost decreased from 13.35% to 12.89%.   Other expenses fell from 19.62% to 16.18%.   

Other income rose 19.70% to Rs 79 crore.  PBIDT rose 46.47% to Rs 810 crore.  Provision for interest remained nil.  Loan funds declined from Rs 4.00 crore as of 31 March 2023 to Rs 3.00 crore as of 31 March 2024.  Inventories rose to Rs 3,184.00 crore as of 31 March 2024 from Rs 3,000.00 crore as of 31 March 2023.  Sundry debtors were higher at Rs 2,156.00 crore as of 31 March 2024 compared to Rs 1,793.00 crore as of 31 March 2023.  Cash and bank balance declined from Rs 4,214.00 crore as of 31 March 2023 to Rs 3,980.00 crore as of 31 March 2024.  Investments rose to Rs 82.00 crore as of 31 March 2024 from Rs 77.00 crore as of 31 March 2023 .  

PBDT rose 46.11% to Rs 808 crore.  Provision for depreciation rose 9.20% to Rs 95 crore.  Fixed assets increased to Rs 5,513.00 crore as of 31 March 2024 from Rs 4,929.00 crore as of 31 March 2023.  Intangible assets declined from Rs 5.00 crore to Rs 4.00 crore.  

Profit before tax grew 53% to Rs 713.00 crore.  Share of profit/loss were nil in both the periods.  Provision for tax was expense of Rs 175 crore, compared to Rs 145 crore.  Effective tax rate was 24.54% compared to 31.12%.

Minority interest was nil in both the periods.  Net profit attributable to owners of the company increased 67.60% to Rs 538.00 crore.  

Equity capital stood at Rs 53.00 crore as of 31 March 2024 to Rs 53.00 crore as of 31 March 2023.  Per share face Value remained same at Rs 2.00.  

Promoters’ stake was 51.92% as of 31 March 2024 ,compared to 51.94% as of 31 March 2023 .  

Full year results analysis.

Net sales (including other operating income) of Divis Laboratories has increased 1% to Rs 7845 crore.  Operating profit margin has declined from 30.49% to 28.11%, leading to 6.88% decline in operating profit to Rs 2,205.00 crore.  Raw material cost as a % of total sales (net of stock adjustments) increased from 38.84% to 40.63%.   Purchase of finished goods cost fell from 0.28% to 0.08%.   Employee cost increased from 12.59% to 13.75%.   Other expenses rose from 17.70% to 17.81%.   

Other income fell 1.74% to Rs 339 crore.  PBIDT fell 6.23% to Rs 2544 crore.  Provision for interest rose 200% to Rs 3 crore.  Loan funds declined from Rs 4.00 crore as of 31 March 2023 to Rs 3.00 crore as of 31 March 2024.  Inventories rose to Rs 3,184.00 crore as of 31 March 2024 from Rs 3,000.00 crore as of 31 March 2023.  Sundry debtors were higher at Rs 2,156.00 crore as of 31 March 2024 compared to Rs 1,793.00 crore as of 31 March 2023.  Cash and bank balance declined from Rs 4,214.00 crore as of 31 March 2023 to Rs 3,980.00 crore as of 31 March 2024.  Investments rose to Rs 82.00 crore as of 31 March 2024 from Rs 77.00 crore as of 31 March 2023 .  

PBDT fell 6.31% to Rs 2541 crore.  Provision for depreciation rose 10.20% to Rs 378 crore.  Fixed assets increased to Rs 5,513.00 crore as of 31 March 2024 from Rs 4,929.00 crore as of 31 March 2023.  Intangible assets declined from Rs 5.00 crore to Rs 4.00 crore.  

Profit before tax down 8.70% to Rs 2,163.00 crore.  Share of profit/loss were nil in both the periods.  Provision for tax was expense of Rs 563 crore, compared to Rs 545 crore.  Effective tax rate was 26.03% compared to 23.01%.

Minority interest was nil in both the periods.  Net profit attributable to owners of the company decreased 12.28% to Rs 1,600.00 crore.  

Equity capital stood at Rs 53.00 crore as of 31 March 2024 to Rs 53.00 crore as of 31 March 2023.  Per share face Value remained same at Rs 2.00.  

Promoters’ stake was 51.92% as of 31 March 2024 ,compared to 51.94% as of 31 March 2023 .  

Cash flow from operating activities decreased to Rs 1,261.00 crore for year ended March 2024 from Rs 2,459.00 crore for year ended March 2023.  Cash flow used in acquiring fixed assets during the year ended March 2024 stood at Rs 1,003.00 crore, compared to Rs 473.00 crore during the year ended March 2023.  

Other highlights

The board recommended a final dividend of Rs 30 per equity share of face value Rs 2 each for the financial year 2023-24. Record date for the purpose of the payment of dividend is August 02, 2024.


Divis Laboratories : Consolidated Results
 Quarter endedYear ended
Particulars202403202303Var.(%)202403202303Var.(%)
Net Sales (including other operating income)2,303.001,951.0018.047,845.007,767.001.00
OPM (%)31.7424.96678 bps28.1130.49-238 bps
OP731.00487.0050.102,205.002,368.00-6.88
Other Inc.79.0066.0019.70339.00345.00-1.74
PBIDT810.00553.0046.472,544.002,713.00-6.23
Interest2.000-3.001.00200.00
PBDT808.00553.0046.112,541.002,712.00-6.31
Depreciation95879.2037834310.20
PBT713.00466.0053.0021632369-8.70
Share of Profit/(Loss) from Associates00-00-
PBT before EO71346653.0021632369-8.70
EO Income00-00-
PBT after EO71346653.0021632369-8.70
Taxation17514520.695635453.30
PAT53832167.6016001824-12.28
Minority Interest (MI)00-00-
Net profit53832167.6016001824-12.28
P/(L) from discontinued operations net of tax00-00-
Net profit after discontinued operations53832167.6016001824-12.28
EPS (Rs)*20.2712.0967.6060.2768.71-12.28
* EPS is on current equity of Rs 53.09 crore, Face value of Rs 2, Excluding extraordinary items.
# EPS is not annualised
bps : Basis points
EO : Extraordinary items
Figures in Rs crore
Source: Capitaline Corporate Database


Previous News
  Divis Laboratories
 ( Results - Analysis 11-Feb-22   17:21 )
  Divi's Laboratories consolidated net profit rises 45.63% in the September 2020 quarter
 ( Results - Announcements 07-Nov-20   13:38 )
  Divis Laboratories Ltd soars 1.13%, up for fifth straight session
 ( Hot Pursuit - 04-Apr-24   13:00 )
  Divi's Laboratories standalone net profit rises 45.48% in the September 2020 quarter
 ( Results - Announcements 07-Nov-20   13:26 )
  Divis Laboratories Ltd soars 1.69%, gains for fifth straight session
 ( Hot Pursuit - 02-Jul-21   13:00 )
  Divis Laboratories Ltd spurts 1.38%, gains for fifth straight session
 ( Hot Pursuit - 06-Apr-23   13:00 )
  Divis Laboratories Ltd gains for third straight session
 ( Hot Pursuit - 03-Sep-19   13:05 )
  Divis Laboratories Ltd jumps nearly 2%
 ( Hot Pursuit - 07-Feb-20   13:05 )
  Divi's Laboratories standalone net profit declines 19.48% in the March 2017 quarter
 ( Results - Announcements 27-May-17   11:01 )
  Divis Laboratories Ltd spurts 0.4%, up for fifth straight session
 ( Hot Pursuit - 28-Sep-22   13:01 )
  Board of Divis Laboratories recommends Final Dividend
 ( Corporate News - 22-May-23   16:04 )
Other Stories
  Apollo Hospitals Enterprise
  04-Jun-24   10:04
  ITL Industries
  01-Jun-24   02:14
  International Combustion (India)
  31-May-24   11:32
  Fluidomat
  31-May-24   11:28
  ISGEC Heavy Engineering
  31-May-24   11:24
  Sreeleathers
  31-May-24   11:20
  Cummins India
  31-May-24   11:18
  Bata India
  31-May-24   09:55
  Tata Steel
  31-May-24   08:36
  India Nippon Electricals
  31-May-24   07:03
Back Top